Medicare will launch the GLP-1 Bridge Program to provide weight-loss GLP-1 medications to eligible seniors, with limited qualification and high monthly costs. Guidance for non-senior patients emphasizes dietary management and prioritizing protein and fiber to mitigate side effects and nutrient concerns. In youth obesity care, GLP-1 receptor agonists have become the default treatment, with exclusive GLP-1 use rising sharply and bariatric surgery declining, though guidance on sequencing therapies remains unclear. GLP-1 drugs work by regulating insulin, slowing gastric emptying, and signaling satiety, and their indications are expanding beyond diabetes and weight management to kidney disease, heart risk, and possibly eating disorders. Clinicians describe GLP-1s as transforming obesity management by addressing physiological and motivational factors, while noting ongoing challenges in public understanding and access.